Riamilovir

Riamilovir Uses, Dosage, Side Effects, Food Interaction and all others data.

Riamilovir is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Riamilovir has shown promise in reducing influenza disease severity and associated complications. Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Riamilovir as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.

Table Of contents

• Riamilovir
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Riamilovir
Generic	Triazavirin
Triazavirin Other Names	Riamilovir, Triazavirin
Type
Formula	C5H4N6O3S
Weight	Average: 228.19 Monoisotopic: 228.006559187
Protein binding	Data regarding the protein binding of triazavirin is not readily available.
Groups	Experimental
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Riamilovir is an antiviral used to treat several strains of influenza.

Riamilovir was developed in Russia as a potential treatment of Influenza A and B infections.

How Riamilovir works

Riamilovir is a guanosine nucleotide analog that inhibits RNA synthesis.

Toxicity

The intraperitoneal LD₅₀ of triazavirin in mice is 1400±120mg/kg in mice and the intragastric LD₅₀ is 2200±96mg/kg.

Patients experiencing an overdose may present with nausea, vomiting, dyspepsia, and stomach pain. Treat overdose with symptomatic and supportive treatment, which may include discontinuation of treatment.

Food Interaction

• Take with or without food.

Volume of Distribution

In rabbits, intragastric triazavirin has a volume of distribution of 83.5±19.2L/kg while intravenous triazavirin has a volume of distribution of 1.2±0.3L/kg.

Elimination Route

In rabbits, intragastric triazavirin reaches a C_max of 1.1±0.1mg/L, with a T_max of 0.40±0.16h, and an AUC of 3.10±0.8mg*h/L. In rabbits, intravenous triazavirin has an AUC of 1.2±0.3mg*h/L.

In humans, triazavirin reaches a C_max of 4.8µg/mL, with a T_max of 1-1.5h, and an AUC of 12.8µgµg/h*mL.

Half Life

In rabbits, intragastric triazavirin has a half life of 1.1±0.1h while intravenous triazavirin has a half life of 0.50±0.09h.

The half life of triazavirin is 1-1.5h.

Clearance

In rabbits, intragastric triazavirin has a clearance of 37.0±11.2L/h*kg while intravenous triazavirin has a clearance of 14.0±3.7L/h*kg.

The clearance of triazavirin is 246mL/min.

Elimination Route

Data regarding the route of elimination of triazavirin is not readily available.

Innovators Monograph

You find simplified version here Riamilovir